Eterna Therapeutics (US:ERNA) Globenewswire·2025-09-29 12:30Core Insights - Ernexa Therapeutics is participating in the 5th Annual iPSC Drug Development Summit, highlighting its innovative cell therapies for advanced cancer and autoimmune diseases [1][4] - The company is advancing a synthetic iMSC approach, which aims to provide scalable, allogeneic, off-the-shelf treatment options without the need for patient-specific cell harvesting [2][5] - Ernexa is developing two key products: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune diseases, with recent data showing ERNA-101's potential to restore a "hot" immune microenvironment in high-grade serous ovarian cancer [3][6] Company Overview - Ernexa Therapeutics focuses on engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) to create innovative therapies for cancer and autoimmune diseases [5][6] - The lead product, ERNA-101, is designed to activate and regulate the immune system's response against cancer cells, while ERNA-201 targets inflammation in autoimmune diseases [6] Industry Context - The iPSC Drug Development Summit serves as a global forum for industry leaders, researchers, and innovators to discuss advancements in iPSC-based therapies [4] - The event will feature discussions on the investment landscape and novel opportunities within the iPSC space, indicating a growing interest and potential in this sector [8]